CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
38 hedge funds and large institutions have $33.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
5% less funds holding
Funds holding: 40 → 38 (-2)
14% less capital invested
Capital invested by funds: $39.2M → $33.7M (-$5.54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$5.18M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$3.89M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.07M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$726K |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$334K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$176K |
| 2 |
Two Sigma Investments
New York
|
-$35.4K |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$25K |
| 4 |
Goldman Sachs
New York
|
-$21K |
| 5 |
Morgan Stanley
New York
|
-$13.9K |
CTIC Hedge Fund Activity: Q1 2020 in Review
38 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2020, worth a combined $33.7M — down 14% from $39.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CTIC positions and 6 closed out — a net gain of 1 holder — while 12 added to existing stakes and 4 trimmed.
The largest buyer was OrbiMed, adding an estimated $5.18M. The largest seller was JP Morgan Chase, cutting an estimated $176K.
- 38 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2020, down from 40 in Q4 2019.
- Funds reported $33.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2020, down 14% quarter-over-quarter.
- 7 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2020 and 6 closed out, a net change of +1 holder.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2020 was OrbiMed, an estimated $5.18M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2020 was JP Morgan Chase, an estimated $176K sold.
Based on aggregated 13F filings for Q1 2020.